@FierceBiotech: Sanofi launches a new antibiotics effort, teams with Fraunhofer. More | Follow @FierceBiotech
@JohnCFierce: Interesting to see Chelsea Therapeautics win the solid backing of the adcomm. Now back to the FDA, where the weather has been much chillier. Odds on OK? | Follow @JohnCFierce
@DamianFierce: Regeneron, Bayer reach for the old Eylea magic with combo AMD deal. Yesterday's story | Follow @DamianFierce
@EmilyMFierce: Omnibus bill would restore $1B in funding to NIH. Story from FierceBiotech Research | Follow @EmilyMFierce
> Zafgen revealed initial results from its Phase IIa study of beloranib, a selective inhibitor of methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome (PWS), a severe form of genetic obesity. The results showed improvements in body weight, hunger-related behaviors, and body composition. Study subjects also lost body fat and preserved lean body mass following four weeks of treatment. Release
> Massachusetts General Hospital and the Broad Institute are partnering up with Amgen ($AMGN) to find new therapeutic targets and develop novel therapies for inflammatory bowel disease. Release
@FierceMedDev: Covidien's ventilator recall gets hit with FDA's 'most serious' Class I label. More | Follow @FierceMedDev
@MarkHFierce: The latest weekly edition of FierceDiagnostics is all ready for you, now with added biomarker coverage. Check it out. Issue | Follow @MarkHFierce
@MichaelGFierce: Roche's delivery method 'shuttles' Alzheimer's drugs past blood-brain barrier. Story from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Qiagen and Exosome inked a Dx development deal to create cancer biomarkers. Yesterday's story | Follow @EmilyWFierce
> Struggling Sequenom's Mayo Clinic deal expands the reach of its prenatal Dx. Story
> Medtronic and Edwards take heart valve rivalry to hospital admins. Report
> Omnibus bill would restore FDA user fees; AdvaMed, MDMA applaud. News
Pharma News
@FiercePharma: Novo Nordisk eyes IPO for its IT subsidiary, taps new CFO to lead review. Story | Follow @FiercePharma
@TracyStaton: Best-read FiercePharma Tuesday: Merck CEO: We'll decide on animal health, consumer biz by year-end. Story | Follow @TracyStaton
@EricPFierce: McKesson fails to get EU drug distributor Celesio. Some see the miss as a shame for both. Story from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: Drug buyers sue Novo Nordisk over 'wrongful' delays to diabetes generic. Yesterday's story | Follow @CarlyHFierce
> Merck recall depletes supplies of new cholesterol drug. Item
> Lilly CEO Lechleiter predicts big things after its 'most financially challenging year.' Piece
> Glaxo CFO: China sales on the rebound after that big hit from the bribery scandal. Story
Drug Delivery News
> Roche's delivery method 'shuttles' Alzheimer's drugs past the blood-brain barrier. Story
> 'On-off' switch in disguised nanoparticles shows delivery potential. Story
> Cynapsus' sublingual strip for severe Parkinson's reduces side effects in a study. Story
> Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019. Item
> Elixir places first DESolve drug-eluting stent in patient. Article
> Amid RNAi buzz, Arcturus touts positive preclinical results. More
Diagnostics News
> J&J will link with a Seattle Dx outfit on a biomarker discovery program. Story
> Ovarian cancer biomarker could predict treatment response and help prevent metastasis. Story
> Microlin Bio files for a $25M IPO to advance cancer Dx and Rx treatments. Story
> Dutch research hospital teams with Probiodrug to assess Alzheimer's biomarker assays. Story
> Dako joins with Merck to concoct cancer treatment companion Dx tests. Article
> Quest seals 3 new Dx development deals. Item